Understanding how misfolded alpha syneclein spreads in the brain and how to stop it's spread

[MarkPrana]

Interesting research about an existing cancer drug with potential to help in PD:

neurosciencenews.com/parkin...

[BeedieBird]

I also just now read this. Very interesting news.

[park_bear]

Wow. This offers the very real possibility of halting progression with an already approved drug. This is a really big deal. Research published here: nature.com/articles/s41467-...

On the downside this medication requires an IV infusion. It is actually a combination of two anti-cancer drugs. I looked up one of them and the cost is more than $7,000 monthly. So as a practical matter this would need to be tested and approved for Parkinson’s and a funding mechanism put in place.

[Boscoejean in reply to park_bear]

so it is good you know how to do the research and it would be nice if it did not take a high level of detective work to actually find out when it may be generally available and how someone could access it even though as you say the cost might be a problem

[kevowpd]

Ted Dawson says the next steps would be to conduct anti-Lag3 antibody trials in mice with Parkinson’s disease and Alzheimer’s disease.

I wouldn't get too excited just yet, but I'm in agreement that it's interesting and a worthwhile post.

[gomelgo in reply to kevowpd]

Mice ... again. Will the waste never stop?

[WinnieThePoo]

like kevowpd said. Also the debate about a-syn as cause of or response to the problem

Also its a cancer drug. Actually 2 cancer drugs in combination therapy. Adverse events have different significance for a drug taken for a relatively short time to fight something that would otherwise kill you, compared to long term treatment of a chronic disorder

"Consistent with the anticipated outcomes, nivolumab is better tolerated than ipilimumab and has long-term treatment advantages (Ascierto et al., 2020). In addition, clinical trials have demonstrated that nivolumab monotherapy or nivolumab plus ipilimumab combination therapy also has positive effects on patients with metastatic uveal melanoma or active melanoma brain metastases (Long et al., 2018; Pelster et al., 2021). Meanwhile, the patent containing the administration of a combination of nivolumab and ipilimumab in a ratio of 1:3 was granted in Europe in 2020 (SADINENI et al., 2020). However, similar to ipilimumab monotherapy, both nivolumab monotherapy (29%) and nivolumab plus ipilimumab combination therapy (71%) had a high incidence of grade 3-4 treatment-related adverse events (Livingstone et al., 2022)."

Interesting. And evidence of tons of research into PD. That brings closer the day something big arrives to fix PD

[Boscoejean]

mayoclinic.org/drugs-supple...

[Boscoejean]

Medical uses

The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.

en.wikipedia.org/wiki/Nivol...